pioneering At Jay. to the we have for I a to you, Bio, am disorders. medicines discover Thank the to complex thrilled neurodevelopmental new neurodegenerative way pipeline. discuss Vyant Vyant and are opportunity
We the due predictive drugs drug machine to novel efficacy. disease, at patient-derived CNS human, platform to scale Most developed This biology have poor drug where available is animal drug of combines a learning models especially candidates. have challenges development, value. fail and brain in models CNS lack CNS discovery the discover the clinic of organoid that
data designed support of some candidates that setting efficacy. share lead potentially you identify are VYNTXXXX. compound, at is which the exciting is I validation identification the program we to to stages have therapeutic for with approach with active our a on assume models today, been working a clinical disease the of to early Our and have allow us animal bypassing to the need
diseases Our support the with would novel discovery first the noted identification in of we drug two phase our two hit candidates the R&D teams. lead rare are
being microBrain XD as venture through machine selection including on work partners, which our AI on the done by well process, collaboration to for proprietary our our biology of system. platform, and screening be compound We analytics high our have done the joint more chemistry, is own interrogating as an the through learning technologies throughput own iterative application on partner
late hoping XXXX. progressed are to in We year candidates programs selection report this for these candidate lead early to and clinical our
focused in discovery to platform. continuing are We our scientific refine -- approach our validating drug human-first
of we patient-derived derive of models scientific A from brain element be Our the disease our therapeutic investigation of identification drive amenable reproducible robust is sufficiently use screening. development biology stem quantitative human signals of and cells relevant drug of advancement. meaningful type the drug to to biomarkers pioneered to human induced key organoids on targets and the physiology efficacy are high from provide that that our preclinical derived of based disease throughput has strategy compound team to human pluripotent hypotheses of of
biological this competitive As accelerate establish discovery to technology platform, our derived we is discovery platform we our for most of models employ that to our established To end, aggregation purpose our for and analysis knew established innovative our we data primarily and the and machine advantage. built files models. efforts organoids CNS processing, storage drug proprietary the that drug of downstream use needed images in large activity, a containing learning we progressing, AnalytiX digital technologies data from
severe in readable assessment milestones developed drug states, a the on to mutations MECPX. abilities data equipment effects directly relevant X of adverse and they into begin features developmental from gained. sets events. six to to designs called that of between children hallmark possible their enable had to in biologically profiling laboratory to efficient leads usually speak, process an the sourced nearly eat constant translate neurological process quantified We large or even to spectrum every the life, toxicity of Syndrome characterization aspect child's is representations experiment and affecting of of ability disorder The and extract autism disease lab near have hand Rett the from machine impairments the recognized and movements breathe unbiased or rare genetic Rett treatment the is including caused months chromosome miss lose seizures. is they gene by easily. primarily the of Rett Rett to XX as is walk, repetitive a formats,
see systems this a the a in controlled high including different spheroids on can program the fashion exhibit you tissue specific extract such from disease others. brain We spheroids morphology, of frequency and used markedly the wave be peak organoids and specific slide, as AssayAnalytiX that Rett our the Rett to quantify imaging right, like disease can showing is features our spheroids things peak As kinetic functional measured FLIPR. on of heights healthy among and forms throughput using phenotype that unique
ongoing promising library on basis multiple a middle Syndrome parameters target International Foundation dependent As summarized were treatment the independent that the two drug form. to rescue screens are drug VYNTXXXX, the phenotypic that target programs correlated in right, phenotype. exhibit compounds that and individual that graph robust novel spheroids. organoids. patient-derived the on of super dependent need to against neurospheroids us Rett our the experiments can on ability phenotype is have concentrations shown our that not slide, repurposing the Rett. identified by occurs shows of and screen chronic Rett shows of a slide across phenotype rescue reproducibly functional pipe the this may that Rett consistent screen parameter VYNTXXXX of ability our with disease A candidate, provides in of smart to directed focused The and engagement spider currently We rescue two for based candidates generate dose the differences full on distinct targets several functional it for on is shows at which in engagement. rescue This is the data individual nanomolar wave following that Rett plot of dose This Rett provided the
and data, for VYNTXXXX disease are approved The FDA organoids human to medication XXXX Rett repurposing VYNTXXXX repurposing the by dose Foundation exhibits an safety of of readily a and for there our Importantly, concentration VYNTXXXXis Rett are Drug working several new already request rescue Rett related patient-derived a known QX dependent several of for International dementia been with Rett to candidate these promising brain. phenotypes candidate reasons. to The reach application Alzheimer's available a investigational disease molecule the consistent in cognition-enhancing has as Syndrome the levels is the Orphan and file we Designation. and drug in compound
are FDA. with committee prepare to meeting trial IRS May the a We pre-IND clinical the of the for meeting in with
pursuing Rett partner, against venture Atomwise. our joint directed targets two also compounds in for are collaboration We novel additional with
relationship rescue. vitro and binding between phenotypic functional compound machine and applying for cell-based of targets the learning potency target to these are We to drive examine and assays establishing degree are progression in
seizures, biochemical distinct delay, from identify identify and We're novel recent action targets Rett of onset condition by a exhibit obtained that dysfunction. differentiated in by neurodevelopmental mechanism evidence and epileptic have motor clinical early candidates and expect intellectual we characterized XXXX and potential the first the VYNTXXXX both on We a is excited clinically candidates half CDKLX Rett candidates. candidates of lead to in XXXX. therapeutic Disorder advanced act our most
understood. Although crucial CDKLX for to not link patient targets are proper and brain pathophysiological development, currently precise the symptoms of its
is we recently versus While and rare drug is testing higher of with of CDKLX unmet of an only that available patients a genetic healthy the gene, disease expression CD treatment. in immunostaining. one of mutation study of the phenotype limited of a candidates. CDKLX need currently selected of therapeutic with We the neurons, conducted CDKLX to potential ultra hindered underlying has targets nucleus CDKLX identification correlated CDD approved neurosteroids. vulnerability defined with investigate identify therapeutic discovery mutation by pathophysiology markers a neurodevelopmental To we have the confirmed neurons the which hyperexcitability the medical in is for synaptic RNA-Seq observed patients, mutant levels single knowledge
compounds expression clinical In composed ratio phenotypic of addition, higher past trials drugs, inhibitory custom a molecules of neuron full showed of astrocyte identified potentially library further range CDD we screened X,XXX resting hyperexcitability manner. confirmatory Approximately novel some approximately Phase markers that both candidates reduction and candidates of phenotype. identify drug We goal panel compounds degree repurposing compounds and molecules of rescue screening of for conducted neurons. and XX for disorder. CDKLX phenotype to of X that observed a a FDA-approved a efficacy, the the with XXX the in We specific produce screening flipper and the GABAergic a CDKLX
currently response dose promising full molecules. curves conducting to are We these
partner candidate screen collaboration addition, approach targets – to we learning machine organoids. utilizing with are a potential Cyclica, three with In for our novel our silico identify CDD collaborating in our molecules screening will we in applying that CDD in
cause. our among have About problems, are and genes, a the XX% of XX% handful slow, genetic a half movements. a XX, is together Parkinson’s in collaboration expertise and modifying area develop potential The Disease with Disease. the glucocerebrosidase Therapeutics Disease called March announced to in neurons identify to discovery gain human is familial hope history to team's disease from the nigra. several Organo high symptoms mutations organized genetics include biology widely expect Disease patient-specific biomarkers pluripotent are compounds a developed and assays environmental On slowly to candidates cases Parkinson's created respective candidate lead poorly of molecular, PD pathology. expected progressive identify biochemical muscle that gait of a balance and of the with and and drug dopamine-producing We the of first utilize cells years XD Disease and phenotype. through Cyclica we to and the result the of is brings can understood advance affects that recapitulate work chemistry, in others. drug tremors, drugs. induced a the substantia identify in imprecise organoids neurodegenerative approaches end sites but PD rescue that be that people including the of that brain XXXX. lead predominantly Therapeutics combination translatable in machine will has of Parkinson's etiology Parkinson’s complex responses accepted models design specific in insights the factors disorder and from of to over towards throughput Disease using on it stem collaboration Scientists rigidity, to the XXXX patient-derived generally Organo Parkinson's both to identification L-R-R-K-X, family-linked cells, condition, identify PD The proprietary patient-specific the disease-linked and family derived Parkinson’s therapeutic based learning cellular and clinically potential multiple from candidates to familial
the is patient on we GBA By approaches common expect and into focusing focus can population. and on the Parkinson's mutations. initially initial LRRKX be therapeutics much Disease Our familial mutations, causes familial extended these sporadic that potential larger to identify linked
across two science and Through cross-site teams, of and repurposed identifying Minnesota. our novel and fully we made sites discoveries the Diego, data California Rett R&D teams of for have research that for am we In work first quarter XXXX over executing believe of PD, accelerate our of actively to progress the Our a proud globe. therapeutics differentiated important are Maple working integrated about made the patients we have biology million the has action treatment our a become method collaboration the around a team close novel in very team XX the candidates. discover on cross-functional plan seamlessly a and I Grove, disease and summary, debilitating will of San impacting
neurodevelopmental team strategic has on service-related with working to to the Diego Finally, our execute R&D work from vision causes neurodegenerative to between our our closely for Andy? medicines death new a turn disorders, CFO. become disability call now fully-integrated over the worldwide. team doing Maple Andy completed back to Grove transition San and Thank And attention. successfully you and I LaFrence, discover of your team major the
